Resonance Medicine

Resonance was founded in 2021, with a technical team composed of Liu Ruxi, his laboratory member Travis Blum, Harvard University professor Min Dong, and University of California, San Francisco researcher Jim Wells. The company plans to revolutionize the treatment of protein-related diseases by reprogramming the specificity of proteases. Resonance's core technology is the development of protein cleavage therapy, which involves redesigning and reprogramming protein cleavage enzymes to enable them to specifically cut and edit target proteins for the treatment of protein-related diseases.